@Article{,
AUTHOR = {Kaili Mao, Cécile Badoual, Philippe Camparo,
Nicolas Barry Delongchamps, Annick Vieillefond,
Anh-Tuan Dinh-Xuan, Michaël Peyromaure},
TITLE = {The prognostic value of vascular endothelial  growth factor (VEGF)-A and its receptor in  clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {15},
YEAR = {2008},
NUMBER = {5},
PAGES = {4257--4262},
URL = {http://www.techscience.com/CJU/v15n5/62255},
ISSN = {1488-5581},
ABSTRACT = {<b>Objectives:</b> To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer.<br/>
<b>Methods:</b> One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed.<br/>
<b>Results:</b> After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP.<br/>
<b>Conclusions:</b> Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.},
DOI = {}
}